Fig. 3From: Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritisTreatment-emergent adverse events per 100 patient-years by years of treatment. AE: adverse event; D/C: discontinuation; IXE: ixekizumab; NMSC: non-melanoma skin cancer; PY: patient-years; SAE: serious adverse eventBack to article page